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Key messages
What is already known about this subject?
 ► Osteoarthritis (Oa) is a serious disease; however, 
its relationship with mortality is unclear due to het-
erogeneity between studies and differences in ap-
proaches to the inclusion of covariates.
 ► While studies have adjusted for potential confound-
ing and used regression modelling to highlight im-
portant covariates, they have not clearly identified 
the mechanisms that increase the risk of mortality 
in people with Oa, which will inform future manage-
ment and preventative strategies.
What does this study add?
 ► the study uses a technique for mediation within a 
survival model to identify the pathways and modi-
fiable targets to reduce mortality in people with Oa.
How might this impact on clinical practice?
 ► it highlights the need to focus on the impact, in addi-
tion to the condition itself, to reduce mortality in the 
large and growing number of people with Oa.
 ► Focusing on encouraging people to walk frequently 
or ‘get out and about’ is important for reducing mor-
tality in people with Oa; while depression, anxiety 
and unrefreshed sleep appear to have a role, the 
clinical significance is low.
AbstrAct
Objectives to identify potentially modifiable factors 
that mediate the association between symptomatic 
osteoarthritis (Oa) and premature mortality.
Methods a population- based prospective cohort study; 
primary care medical record data were linked to self- 
report information collected by questionnaire in adults 
aged 50 years and over (n=10 415). Oa was defined 
by primary care consultation and moderate- to- severe 
pain interference in daily life. a cox proportional hazards 
analysis determined the total effect (te) of Oa on mortality 
after adjustment for potential confounders. Within the cox 
model, path analysis was used to decompose the te to 
assess the indirect and direct effects for selected potential 
mediators (anxiety, depression, unrefreshed sleep and 
walking frequency). results are expressed as Hrs with 
95% cis derived from bootstrap resampling.
Results Oa was significantly associated with mortality 
(te- adjusted Hr 1.14; 95% ci 1.00 to 1.29). the indirect 
effects for walking frequency were 1.05 (95% ci 1.04 to 
1.06), depression 1.02 (95% ci 1.02 to 1.03), anxiety 1.01 
(95% ci 1.00 to 1.02) and unrefreshed sleep 1.01 (95% ci 
1.00 to 1.01).
Conclusions the analysis indicates that encouraging 
people to walk and ‘get out and about’ in addition to 
targeting Oa could be protective against excessive 
mortality. the findings also suggest that depression, 
anxiety and unrefreshed sleep have a role in premature 
mortality for people with Oa; however, this has low clinical 
significance.
InTROduCTIOn
There is increasing interest in mortality as an 
outcome of osteoarthritis (OA) due to the 
sheer frequency and expected increase in 
the prevalence of the condition, and signif-
icant association with comorbidities, such 
as cardiovascular disease (CVD).1–3 Meta- 
analysis of studies examining the relationship 
between OA and mortality have highlighted 
conflicting results; however, this is due to 
differences in case and mortality definitions, 
selection of confounders and selection bias.4–6 
More recent reviews highlight a positive asso-
ciation between lower limb OA and cardio-
vascular mortality1 7; there have been reports 
of positive associations between radiographic 
knee OA and cause- specific mortality (CVD, 
diabetes and renal disease),8 symptomatic 
knee pain and cardiovascular mortality,9 and 
doctor- diagnosed OA with mortality linked 
to heart failure.10 Walking disability has been 
linked to the increased link between lower 
limb OA and mortality.4 11 12
Understanding links between OA and all- 
cause mortality remains important to allow 
comparisons with other health conditions. 
Recent studies in the USA have highlighted 
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Figure 1 Proposed pathways between osteoarthritis and 
mortality; direct and indirect effects through low walking 
frequency, depression, anxiety and unrefreshed sleep.
BMI, body mass index.
a positive association between symptomatic lower limb 
OA and all- cause mortality.7 While studies have adjusted 
for potential confounding and used regression model-
ling to highlight important covariates, the mechanisms 
that increase the risk of all- cause mortality in people with 
OA, which will inform future management and preven-
tative strategies, are under- researched.1 3–12 It is unclear 
whether the increased risk is due to the OA itself or to 
its impact which forms pathways to premature mortality. 
This paper builds on previous work to examine poten-
tial pathways that explain the link between OA and all- 
cause mortality with the aim of identifying modifiable 
targets.13–15 Physical disability, which often follows lower 
limb OA,13 14 has been identified as one mechanism that 
explains the increased risk of mortality, and is a target 
for healthcare.15 Infrequent walking and physical activity, 
which is associated with physical disability and premature 
mortality,16 may be a target that is relevant to all with OA 
(not only those with physical disability) and be part of 
self- management, optimal primary care and prevention 
of other comorbidities that may increase mortality risk, 
such as CVD and diabetes.17 The analysis also explores 
the role of mood (anxiety and depression) and unre-
freshed sleep; it is possible that OA increases anxiety, 
depression and unrefreshed sleep which leads to prema-
ture mortality (figure 1).18–21 Mediation analysis is used 
to investigate pathways, although this has rarely been 
undertaken using survival analysis due to the challenge of 
accounting for time. The aim of this study was to examine 
potential mechanisms of the impact of OA on all- cause 
mortality, based on a novel technique for mediation anal-
ysis within a survival model. Specifically, the study tests 
the hypotheses that premature mortality is associated 
with symptomatic OA and is mediated through walking 
frequency, depression, anxiety and unrefreshed sleep.
MeTHOds
 design, study setting and population
The North Staffordshire Osteoarthritis Project 
(NorStOP) is a population- based prospective cohort 
study.22 The sampling frame comprised individuals aged 
50 years and over who were registered to receive care 
from one of six general practices in North Staffordshire, 
UK, gave written consent for medical record review and 
were mailed a baseline questionnaire, between April 2002 
and May 2003, which collected data on health and socio-
demographic factors. In the UK, general practice regis-
ters offer a convenient sampling frame for population- 
based studies; an estimated 98% of the UK residents are 
registered. Reminders were sent to non- responders 2 and 
4 weeks after the initial mailing.
Of 10 432 potential participants who gave consent to 
medical record review, OA status could be determined 
for all; however, 17 (0.16%) had missing data on vital 
status (figure 2); this figure was deemed negligible and 
these 17 participants were removed from the analysis. 
Of the remaining 10 415 participants, 2233 (21.4%) did 
not have complete data on mediators and confounders; 
participants with incomplete data were on average signifi-
cantly older and more likely to be female. To obtain 
data for the primary analyses, multiple imputation by 
chained equations was used to impute missing data23 
in Stata V.13. All confounders, mediators and outcome 
were used in the multiple imputation model; logit regres-
sion models were specified for binary variables and one 
skewed continuous variable (cognitive behaviour) was 
normalised prior to imputation, and transformed back to 
its original scale afterwards. The two- stage calculation was 
used to determine the number of required imputations, 
which was 32.24
Identification of OA
A combination of medical record and questionnaire data 
was used to identify symptomatic OA.25 General practi-
tioners in the study used the hierarchical Read code 
system to code the reasons for clinical encounters in 
primary care consultations.26 Morbidity data (ie, symp-
toms and diseases) in this system are grouped under 
19 main Read chapters. Data collected at the second 
hierarchical level or above were used to identify diag-
nostic groups. Individuals were defined as having OA 
if they had consulted general practice for OA between 
2000 and 2008 based on Read code N05., and indicated 
moderate- to- severe pain interference on daily life in the 
Medical Outcomes Short Form 36 at baseline.27 As OA is 
a long- standing, often progressive chronic condition, it 
was assumed that a clinician- established diagnosis at any 
point during the study period implied that OA was likely 
present at least to some degree during the entire period 
of observation.
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Figure 2 Flow of study participants. GP, general 
practitioner.
Outcome
Vital status was obtained from the patient registration 
system held at the local primary care trust and from 
dates notified to the NorStOP project team. These later 
dates of death were confirmed using manual tracing 
of the National Health Service Summary Care Record 
Demographic system. The outcome of interest was time 
to death, and was taken as time from the date of base-
line questionnaire completion to the date of death or 
censoring took place. Information on vital status was 
available until 01 October 2012 and this is the censor 
date for those who survived.
Proposed mediators
The technique to perform mediation analysis required 
all mediators to be binary.28–30 Depression and anxiety 
were measured using the Hospital Anxiety and Depres-
sion Scale. Raw scores were categorised as no depression/
anxiety (0–7) or depression/anxiety (possible/probable 
cases; 8–21).31 Walking frequency was measured using 
a single item (‘Thinking about the past 4 weeks, how 
often do you go out for a walk? All/most/some/few/no 
days’). Using the median value, participants indicating 
all/most/some days were considered as frequent walkers 
(high frequency) and few/no days were considered as 
infrequent walkers (low frequency).22 One item from the 
Estimation of Sleep Problems Scale was used to identify 
unrefreshed sleep.32 Participants indicating that they 
experienced difficulties in the non- restorative sleep item 
(‘During the past 4 weeks, did you wake up after your 
usual amount of sleep feeling tired and worn out?’) on 
most nights in the past 4 weeks were classified as having 
unrefreshed sleep and compared with those who experi-
enced no difficulties on some nights.33
Confounders
Comorbidities, sociodemographic and lifestyle factors 
associated with OA and morbidity were included as 
confounders.1 3–14 Medical records were used to iden-
tify ischaemic heart disease, chronic obstructive pulmo-
nary disease and diabetes in the same manner as for 
OA (ie, primary care consultation between 2000 and 
2008). Number of prescriptions for non- steroidal anti- 
inflammatory drugs were also captured during the same 
period, dichotomised at zero, which was the median 
number of prescriptions. To cover all CVD, we included 
self- reported measures and asked responders to indicate 
if they had ‘heart problems’ or ‘raised blood pressure’. 
Age, gender, educational attainment, occupational soci-
oeconomic status, smoking status and cognitive impair-
ment were all reported by questionnaire. Educational 
attainment (finished education on leaving school; gone 
onto full- time education including college or university) 
was included as a proxy measure of lifetime socioeco-
nomic status. Participants’ current or most recent job 
was categorised to non- manual or manual.34 Self- report 
of current smoking status was categorised to current 
versus non- smoker. Cognitive impairment was measured 
using the cognitive and alertness behaviour subscale of 
the Functional Limitations Profile; scores range from 0 to 
100.35 Body mass index (BMI) was calculated from partic-
ipants reported height and weight.
Statistical analysis
Cox proportional hazard modelling was used to obtain 
associations between OA and time to death, presented 
as HRs with 95% CIs. First, unadjusted associations were 
obtained, followed by adjustment for all confounders. 
The proportionality of the hazards assumption was 
assessed via likelihood- ratio test comparing a model 
including time- dependent constructs of all confounders 
to a smaller model including time- fixed constructs only. 
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Censoring was assumed non- informative and was taken as 
the earliest of withdrawal from the study/departure from 
practice or 01 October 2012.
The technique to perform mediation analysis within 
survival analysis was based on a counterfactual frame-
work.28 29 Within the counterfactual framework, each 
participant is observed under one set of circumstances 
and then consideration is given to what would have 
happened under counterfactual circumstances. This 
involves replication of analyses, where in the first 
instance, the exposure takes the original value and in the 
replication, it takes the opposite or counterfactual value. 
Weights are derived from logistic regression of the binary 
mediator on the exposure and confounders.29 When the 
assumptions of proportional hazards and non- informative 
censoring are met, the weighted Cox regression model 
will give HRs which are estimates of the indirect and 
direct effects; the indirect effect is the ‘amount’ of medi-
ation and the extent to which each proposed mediator 
explains the link between OA and mortality, while the 
direct effect is the extent of the remaining link between 
OA and mortality once the indirect effect of the proposed 
mediator is accounted for. The product of these two HRs 
provides the HR for the total effect (TE) (ie, the overall 
association between OA and mortality). CIs were calcu-
lated using bootstrapping to account for the non- normal 
distribution of the.29 This analysis was performed using 
code developed for the statistical package R.29 30
First, associations between OA and each mediating vari-
able were examined using logistic regression; all associa-
tions between OA and potential mediators were adjusted 
for potential confounders and are presented as ORs with 
95% CIs. Results of the mediation analyses (carried out 
using the described technique) are presented as HRs 
for the direct, indirect and total effects with associated 
bootstrapped 95% CIs. Mediation was indicated by the 
presence of a significant indirect effect. The descriptive 
analysis was performed using Stata V.13 and the survival 
and mediation analyses were carried out using R.
sensitivity analyses
Sensitivity of the findings from the primary analyses was 
assessed when only those participants with complete 
mediator and confounder data were used (n=8182). 
Sensitivity analysis was performed to assess the robust-
ness of findings to potential unmeasured confounding, 
using the E value approach introduced by VanderWeele 
and Ding36; E value represents the minimal needed asso-
ciation between a confounder and both the outcome and 
exposure to fully explain observed associations.
ResulTs
Cohort characteristics
Of the 10 415 participants, 3172 (30.5%) of the sample 
had OA (table 1). The mean age was 66.2 years (SD 10.2 
years) and 53.8% were female. The median time from 
the date of questionnaire return to death among those 
who died (1643 (15.8%)) was 2076 days (range 1–3807). 
Table 1 also gives detail on completeness for each of the 
patient characteristics.
Relationship between OA and mortality
Of those with OA, 606 (19.0%) died during the study 
period, compared with 1039 (14.3%) who didn’t have 
OA; median person- time (IQR) of follow- up was 3674 days 
(3461–3835) cf. 3646 days (3472–3834). Figure 3 shows 
survival function plots over 10 years for those with and 
without OA. Incidence mortality rate per 1000 person- 
years was 1.06 among those with OA and 1.04 among 
those without, with unadjusted HR 1.30 (95% CI 1.22 to 
2.30). The association between OA and time to death was 
attenuated when adjusted for confounders; adjusted HR 
was 1.11 (95% CI 1.06 to 1.17). E value associated with 
the estimate was 1.36 (and 1.25 for the lower CI); this is 
the association that an unmeasured confounder would 
have to have with both OA and mortality, conditional 
on measured confounders, to fully explain the observed 
association. The likelihood- ratio test did not reveal a 
significant difference between models with and without 
time- dependent constructs of confounders ( χ2 =11.79, p 
value=0.1078); it is plausible to assume that proportion-
ality of hazards assumption was satisfied.
Mediation of association between OA and mortality
OA was positively associated with all of the proposed medi-
ators (table 2). Corresponding E values are also given 
in table 2. The adjusted indirect effects for low walking 
frequency were 1.05 (95% CI 1.04 to 1.06), depression 
1.02 (95% CI 1.02 to 1.03), unrefreshed sleep 1.01 (95% 
CI 1.00 to 1.01) and anxiety 1.01 (95% CI 1.00 to 1.02). 
Notable attenuation in the direct effects occurred when 
walking frequency was included as a mediator (1.05 (95% 
CI 1.00 to 1.10)). Direct effects for depression, anxiety 
and unrefreshed sleep were 1.08 (95% CI 1.03 to 1.13), 
1.10 (95% CI 1.05 to 1.015) and 1.09 (95% CI 1.05 to 
1.14), respectively.
When analyses were restricted to only those with 
complete mediator and confounder data (n=8182), the 
findings were generally similar; however, analyses based 
on imputed data gave estimates which were closer to the 
null, and more precise (table 3).
dIsCussIOn
This study examined potential mechanisms between 
OA and all- cause mortality within a survival model with 
the aim of identifying potentially modifiable targets for 
healthcare.29 The findings indicate a positive associa-
tion between symptomatic OA and all- cause mortality 
and highlight frequent walking as a potential target to 
reduce all- cause mortality. While anxiety, depression and 
unrefreshed sleep had statistically significant effects, the 
extent of their mediation effect has low clinical signifi-
cance.
While the HRs in the analysis can be considered to be 
low (adjusted HR 1.11 (95% CI 1.06 to 1.17) following 
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Table 1 Characteristics of the study participants (10 415 participants)
Variable
No osteoarthritis Osteoarthritis
n=7243 (69.5%) n=3172 (30.5%)
Death No 6204 (86) 2568 (81)
Yes 1039 (14) 604 (19)
Age, years Mean (SD) 65.3 (10.1) 68.0 (10.1)
Sex Male 3525 (49) 1284 (40)
Female 3718 (51) 1888 (60)
Further education No 6158 (85) 2813 (89)
Yes 930 (13) 269 (8)
Missing 155 (2) 90 (3)
Occupational class Non- manual 3141 (43) 1141 (36)
Manual 3624 (50) 1726 (54)
Missing 478 (7) 305 (10)
Smoking No/previous 4176 (58) 1887 (60)
Current 3003 (41) 1245 (39)
Missing 64 (1) 40 (1)
Cognitive behaviour (0–100)* Median (IQR) 0 (0–13.2) 12.7 (0–37.2)
IHD consultation† No 6760 (93) 2749 (87)
Yes 483 (7) 423 (13)
COPD consultation† No 6972 (96) 2969 (94)
Yes 271 (4) 203 (6)
Diabetes consultation† No 6894 (95) 2897 (91)
Yes 349 (5) 275 (9)
NSAIDs prescription† No 5072 (70) 1488 (47)
Yes 2171 (30) 1684 (53)
Self- report heart condition No 4475 (62) 1507 (48)
Yes 2768 (38) 1665 (52)
Body mass index‡, kg/m2 Mean (SD) 26.2 (4.4) 27.7 (5.2)
Walking frequency High 4257 (59) 1129 (36)
Low 2798 (39) 1974 (62)
Missing 188 (2) 69 (2)
Depression Non- case 5970 (83) 1947 (61)
Possible/probable case 1106 (15) 1143 (36)
Missing 167 (2) 82 (3)
Anxiety Non- case 4785 (66) 1375 (43)
Possible/probable case 2284 (32) 1719 (54)
Missing 174 (2) 87 (3)
Unrefreshed sleep No 6125 (85) 2191 (69)
Yes 907 (12) 900 (28)
Missing 211 (3) 81 (3)
All values are N (%) unless otherwise stated.
*Higher score indicates worse score; based on 6833 and 2940 participants for those without and with OA, respectively.
†Obtained from medical records.
‡Based on 6955 and 3024 participants for those without and with OA, respectively.
COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; NSAIDs, non- steroidal anti- inflammatory drugs.
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Figure 3 Survival probability over 10 years for those with 
and without osteoarthritis (OA).
Table 2 Pathways between osteoarthritis and mortality via walking frequency, depression, anxiety and unrefreshed sleep: 
total, direct and indirect effects
Mediator
Association between 
osteoarthritis and 
potential mediator
Adjusted OR (95% CI) Pathway Adjusted HR (95% CI)
– Total effect (no mediators) 1.11 (1.06 to 1.17)
Walking frequency Direct 1.05 (1.00 to 1.10)
  Frequent walker Reference Indirect 1.05 (1.04 to 1.06)
  Non- frequent walker 1.89 (1.82 to 1.97)* Total 1.10 (1.05 to 1.15)
Depression Direct 1.08 (1.03 to 1.13)
  No depression Reference Indirect 1.02 (1.02 to 1.03)
  Depression 2.10 (2.00 to 2.21)† Total 1.11 (1.06 to 1.16)
Anxiety Direct 1.10 (1.05 to 1.15)
  No anxiety Reference Indirect 1.01 (1.00 to 1.02)
  Anxiety 1.96 (1.88 to 2.05)‡ Total 1.11 (1.06 to 1.16)
Unrefreshed sleep Direct 1.09 (1.05 to 1.14)
  Refreshed sleep Reference Indirect 1.01 (1.00 to 1.01)
  Unrefreshed sleep 1.98 (1.88 to 2.09)§ Total 1.12 (1.08 to 1.17)
All models adjusted for age, sex, education, occupation, smoking status, cognitive behaviour, BMI, consultation for ischaemic heart disease, 
chronic obstructive pulmonary disease, diabetes, non- steroidal anti- inflammatories and self- report of heart conditions.
Significant associations between predictor and mediator and indirect effects are in bold.
*E value for point estimate=2.09; E value for lower CI=2.04.
†E value for point estimate=2.26; E value for lower CI=2.18.
‡E value for point estimate=2.15; E value for lower CI=2.08.
§E value for point estimate=2.16; E value for lower CI=2.08.
BMI, body mass index.
adjustment for other key confounders, the increased link 
of mortality is applicable to a large number of people 
in the general population who have symptomatic OA. 
Walking frequency explained the greatest amount of 
the link between OA and premature mortality (indirect 
effect 1.05 (95% CI 1.04 to 1.06) cf. TE 1.10 (95% CI 1.05 
to 1.15)). The extent of the indirect effect was compa-
rable to that for physical function, measured via speed of 
walking, on the link between radiographic hip OA and 
CVD mortality. This finding also links with previous work 
which has indicated that walking disability is associated 
with premature mortality in older adults with OA,7 8 11 15 
as walking disability leads to reduced walking frequency.3 
However, of the low- frequency walkers with OA, more 
than one in five (22.7%), one in three (34.6%) and 
two of three (65.0%) had little or no limitation walking 
more than one mile, half a mile or 100 yards, respec-
tively, indicating that limitation is not always the barrier 
to frequent walking. Encouraging people to maintain 
levels of walking and physical activity and targeting a 
reduction in physical limitation in clinical practice to 
allow this is important. Low walking frequency is linked 
with a number of anatomical (eg, muscle weakness) and 
physiological impairments (eg, hypercholesterolaemia 
and hypertension) which leads to comorbidity, such as 
CVD and diabetes, which are associated with premature 
mortality.37 Small amounts of regular walking and getting 
out and about can offer protection against comorbidity, 
including depression and CVD.38
While the indirect effects of depression, anxiety and 
unrefreshed sleep can be considered as statistically signif-
icant, the level of clinical significance is debatable. In 
this analysis, 18.2%, 9.1% and 8.3% of the increased risk 
of all- cause mortality in people with OA were explained 
by depression, anxiety and unrefreshed sleep, respec-
tively; although the adjusted association between OA and 
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Table 3 Sensitivity analysis in complete cases (n=8182); pathways between osteoarthritis and mortality via walking 
frequency, depression, anxiety and unrefreshed sleep: total, direct and indirect effects
Mediator
Association between 
osteoarthritis and potential 
mediator Pathway Adjusted HR (95% CI)
– Total effect (no mediators) 1.14 (1.00 to 1.29)
Walking frequency Direct 1.07 (0.96 to 1.26)
  Frequent walker Reference Indirect 1.06 (1.04 to 1.08)
  Non- frequent walker 2.03 (1.82 to 2.26) Total 1.13 (1.02 to 1.33)
Depression Direct 1.09 (0.98 to 1.23)
  No depression Reference Indirect 1.04 (1.02 to 1.06)
  Depression 2.42 (2.11 to 2.77) Total 1.13 (1.01 to 1.27)
Anxiety Direct 1.13 (0.99 to 1.25)
  No anxiety Reference Indirect 1.00 (0.98 to 1.02)
  Anxiety 2.01 (1.80 to 2.26) Total 1.13 (1.00 to 1.26)
Unrefreshed Direct 1.13 (1.01 to 1.28)
  Not unrefreshed Reference Indirect 1.01 (1.00 to 1.03)
  Unrefreshed 2.15 (1.88 to 2.47) Total 1.14 (1.01 to 1.29)
All models adjusted for age, sex, education, occupation, smoking status, cognitive behaviour, BMI, consultation for ischaemic heart disease, 
chronic obstructive pulmonary disease, diabetes, non- steroidal anti- inflammatories and self- report of heart conditions.
Significant associations between predictor and mediator and indirect effects are in bold.
BMI, body mass index.
all- cause mortality is also low (ie, HR 1.14). The role of 
depression, anxiety and unrefreshed sleep on mortality 
is often unclear due to confounding from comorbidity 
and sociodemographic and lifestyle factors,39 although 
in these analyses, all three continued to explain, even if 
small, a role in people with OA. While links with physical 
function may explain part of the mechanism for unre-
freshed sleep, anxiety and depression, further research is 
required to further clarify these pathways. The selection 
of confounders in studies of OA and mortality prompts 
debate over the role of covariates. Obesity was included 
in this study as a confounder, while in other studies, it 
has been highlighted as having a role in mortality for 
people with knee OA.1 7 8 In additional analysis, in this 
study, obesity exerted no significant mediating effect on 
the pathway between OA and mortality (indirect effect 
1.00 (95% CI 0.98 to 1.01)).
The study has a number of strengths. A clinical defini-
tion of OA, which captured the presence of symptomatic 
OA, was used and mortality data were obtained from a 
national data source.25 The diagnoses of OA in medical 
records was dependent on clinicians’ approaches to 
identifying OA and is based on a range of factors linked 
to the clinical syndrome and may include radiographic 
signs; this may lead to misclassification of OA. High 
rates of sensitivity (82%40) and specificity (100%41) have 
been reported for OA identified via medical records but 
these estimates are dependent on the reference stan-
dard selected. The diagnoses of OA in medical record 
may also underestimate the diagnoses of hand OA and 
it is expected that there will only be a small number of 
people classified as having OA who have only hand OA42; 
the majority of those with OA in this study will have lower 
limb OA.
This study was a large, population- based study sampled 
from the general population. The response rate was high 
and was comparable to other population- based studies 
that have used postal questionnaires. The available data 
covered important mediators and confounders of the 
relationship between OA and mortality.1 3–15 Limitations 
of the data were that joint- specific OA was not coded 
in the electronic health record data and cause- specific 
mortality could not be identified; this prevented analysis 
of the relationship with mortality with lower limb OA and 
a focus on CVD which has been identified as the cause 
of mortality most pertinent for OA.7 8 Self- reported data 
was included; while this self- report data can be limited by 
inaccuracies, through recall bias or misinterpretation of 
questions, it is the most appropriate method to collect 
data on the impact of OA. Validated questionnaires were 
used to capture these constructs.22 27 32 To adjust for poten-
tial misclassification of BMI due to discrepancies in self- 
reported height and weight, the analysis was adjusted for 
sociodemographic factors, including age, gender, educa-
tion and occupational status, resulting in a close approx-
imation of actual BMI.43 44 The severity of OA could not 
be identified in this data and maybe a confounder of the 
relationship between OA and mortality and impact on the 
estimates of the indirect and direct effects when media-
tors were examined. In addition, there may be other 
confounders that are significant but were not included 
in this study. Sensitivity analysis indicated that unmea-
sured confounders would need to have a moderate asso-
ciation with OA and mortality in addition to the factors 
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already included to impact on the estimates. The need 
for binary variables for this analysis may result in the loss 
of precision and misclassification.45 46 This also prevented 
examination for trends in the extent of mediation with 
increasing levels of exposures.46
The study is longitudinal in nature; however, OA and 
the mediating and confounding factors were measured 
at the same time point. While modelling the relationship 
and pathways between OA and mortality is challenging, 
the method used in this analysis is currently the best 
approach to understanding the complex relationship.47 
Although the causal inferences indicated by this analysis 
should be interpreted with caution, the findings provide 
empirical support for the proposed theoretical mecha-
nism and targets for interventions.29 47 The analytical 
method used is limited to including one binary mediator 
at a time. This may underestimate the effect of potential 
mediators and also prevents further exploration of the 
complex relationship, for example, identifying reasons 
for the mediating effect of depression and unrefreshed 
sleep, and the further role of comorbidity. Consideration 
of multiple hypotheses simultaneously increased the 
likelihood of a type 1 error48 and it was not possible to 
correct for this here.
This study suggests that further research on under-
standing the link with mortality should focus on clinical/
symptomatic OA. The potential to examine for media-
tion and test pathways within Cox proportional models 
indicate a need to move away from adjusted regression 
models to identify targets for interventions to reduce 
mortality linked to OA. Further development of statistical 
models is required to further understand the complex 
relationship between OA and mortality.
In conclusion, the findings of the study indicate 
the significant relationship between symptomatic OA 
and mortality. The common occurrence of OA in the 
general population indicate clinical and population 
approaches to reduce the impact and reduce mortality. 
This approach to understanding the pathway from OA to 
mortality indicates that walking frequency is a key target 
to reduce mortality; small amounts of frequent walking 
and getting out and about could reduce the extent of 
premature mortality in people with OA. The mediating 
effect of depression, anxiety and unrefreshed sleep was 
of low clinical significance.
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